Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
J Inflamm (Lond). 2011 Dec 7;8:36. doi: 10.1186/1476-9255-8-36.
Zinc supplementation can modulate immunity through inhibition of NF-κB, a transcription factor that controls many immune response genes. Thus, we sought to examine the mechanism by which zinc supplementation tempers the response to a common allergen and determine its effect on allergic airway inflammation.
Mice were injected with zinc gluconate prior to German cockroach (GC) feces (frass) exposure and airway inflammation was assessed. Primary bone marrow-derived neutrophils and DMSO-differentiated HL-60 cells were used to assess the role of zinc gluconate on tumor necrosis factor (TNF)α expression. NF-κB:DNA binding and IKK activity were assessed by EMSA and in vitro kinase assay. Protein levels of A20, RIP1 and TRAF6 were assessed by Western blot analysis. Establishment of allergic airway inflammation with GC frass was followed by administration of zinc gluconate. Airway hyperresponsiveness, serum IgE levels, eosinophilia and Th2 cytokine production were assessed.
Administration of zinc gluconate prior to allergen exposure resulted in significantly decreased neutrophil infiltration and TNFα cytokine release into the airways. This correlated with decreased NF-κB activity in the whole lung. Treatment with zinc gluconate significantly decreased GC frass-mediated TNFα production from bone-marrow derived neutrophils and HL-60 cells. We confirmed zinc-mediated decreases in NF-κB:DNA binding and IKK activity in HL-60 cells. A20, a natural inhibitor of NF-κB and a zinc-fingered protein, is a potential target of zinc. Zinc treatment did not alter A20 levels in the short term, but resulted in the degradation of RIP1, an important upstream activator of IKK. TRAF6 protein levels were unaffected. To determine the application for zinc as a therapeutic for asthma, we administered zinc following the establishment of allergic airway inflammation in a murine model. Zinc supplementation decreased airway hyperresponsiveness and serum IgE levels, but had no effect on Th2 cytokine expression.
This report suggests that the mechanism by which zinc supplementation alters NF-κB activity is via the alteration of A20 activity. In addition, this study provides evidence that supplementation of zinc to asthmatics may alter airway reactivity and serum IgE levels, suggesting zinc supplementation as a potential treatment for asthmatics.
锌补充剂可以通过抑制 NF-κB 来调节免疫,NF-κB 是一种转录因子,控制着许多免疫反应基因。因此,我们试图研究锌补充剂调节对常见过敏原反应的机制,并确定其对过敏性气道炎症的影响。
在德国蟑螂(GC)粪便(粪便)暴露之前,给小鼠注射葡萄糖酸锌,并评估气道炎症。使用原代骨髓衍生的中性粒细胞和 DMSO 分化的 HL-60 细胞来评估葡萄糖酸锌对肿瘤坏死因子(TNF)α表达的作用。通过 EMSA 和体外激酶测定评估 NF-κB:DNA 结合和 IKK 活性。通过 Western blot 分析评估 A20、RIP1 和 TRAF6 的蛋白水平。用 GC 粪便建立过敏性气道炎症后,给予葡萄糖酸锌。评估气道高反应性、血清 IgE 水平、嗜酸性粒细胞增多和 Th2 细胞因子产生。
在过敏原暴露前给予葡萄糖酸锌可显著减少中性粒细胞浸润和 TNFα 细胞因子释放到气道中。这与整个肺中 NF-κB 活性的降低相关。用葡萄糖酸锌治疗可显著降低骨髓衍生的中性粒细胞和 HL-60 细胞中 GC 粪便介导的 TNFα 产生。我们证实了锌介导的 HL-60 细胞中 NF-κB:DNA 结合和 IKK 活性的降低。A20 是 NF-κB 的天然抑制剂,也是一种锌指蛋白,是锌的潜在靶标。锌处理在短期内不会改变 A20 的水平,但会导致 IKK 的重要上游激活剂 RIP1 的降解。TRAF6 蛋白水平不受影响。为了确定锌作为治疗哮喘的应用,我们在小鼠模型中建立过敏性气道炎症后给予锌。锌补充可降低气道高反应性和血清 IgE 水平,但对 Th2 细胞因子表达无影响。
本报告表明,锌补充改变 NF-κB 活性的机制是通过改变 A20 的活性。此外,这项研究提供了证据表明,向哮喘患者补充锌可能会改变气道反应性和血清 IgE 水平,提示锌补充可能是哮喘患者的一种潜在治疗方法。